<?xml version='1.0' encoding='utf-8'?>
<document id="10064571"><sentence text="The aromatase inactivator 4-hydroxyandrostenedione (4-OH-A) inhibits tamoxifen metabolism by rat hepatic cytochrome P-450 3A: potential for drug-drug interaction of tamoxifen and 4-OH-A in combined anti-breast cancer therapy."><entity charOffset="26-50" id="DDI-PubMed.10064571.s1.e0" text="4-hydroxyandrostenedione" /><entity charOffset="52-58" id="DDI-PubMed.10064571.s1.e1" text="4-OH-A" /><entity charOffset="69-78" id="DDI-PubMed.10064571.s1.e2" text="tamoxifen" /><entity charOffset="165-174" id="DDI-PubMed.10064571.s1.e3" text="tamoxifen" /><entity charOffset="179-185" id="DDI-PubMed.10064571.s1.e4" text="4-OH-A" /><pair ddi="false" e1="DDI-PubMed.10064571.s1.e0" e2="DDI-PubMed.10064571.s1.e0" /><pair ddi="false" e1="DDI-PubMed.10064571.s1.e0" e2="DDI-PubMed.10064571.s1.e1" /><pair ddi="false" e1="DDI-PubMed.10064571.s1.e0" e2="DDI-PubMed.10064571.s1.e2" /><pair ddi="false" e1="DDI-PubMed.10064571.s1.e0" e2="DDI-PubMed.10064571.s1.e3" /><pair ddi="false" e1="DDI-PubMed.10064571.s1.e0" e2="DDI-PubMed.10064571.s1.e4" /><pair ddi="false" e1="DDI-PubMed.10064571.s1.e1" e2="DDI-PubMed.10064571.s1.e1" /><pair ddi="false" e1="DDI-PubMed.10064571.s1.e1" e2="DDI-PubMed.10064571.s1.e2" /><pair ddi="false" e1="DDI-PubMed.10064571.s1.e1" e2="DDI-PubMed.10064571.s1.e3" /><pair ddi="false" e1="DDI-PubMed.10064571.s1.e1" e2="DDI-PubMed.10064571.s1.e4" /><pair ddi="false" e1="DDI-PubMed.10064571.s1.e2" e2="DDI-PubMed.10064571.s1.e2" /><pair ddi="false" e1="DDI-PubMed.10064571.s1.e2" e2="DDI-PubMed.10064571.s1.e3" /><pair ddi="false" e1="DDI-PubMed.10064571.s1.e2" e2="DDI-PubMed.10064571.s1.e4" /><pair ddi="false" e1="DDI-PubMed.10064571.s1.e3" e2="DDI-PubMed.10064571.s1.e3" /><pair ddi="false" e1="DDI-PubMed.10064571.s1.e3" e2="DDI-PubMed.10064571.s1.e4" /></sentence><sentence text="Tamoxifen (tam), an anti-breast cancer agent, is metabolized into tam-N-oxide by the hepatic flavin-containing monooxygenase and into N-desmethyl- and 4-hydroxy-tam by cytochrome P-450s (CYPs)"><entity charOffset="0-9" id="DDI-PubMed.10064571.s2.e0" text="Tamoxifen" /><entity charOffset="66-77" id="DDI-PubMed.10064571.s2.e1" text="tam-N-oxide" /><entity charOffset="93-99" id="DDI-PubMed.10064571.s2.e2" text="flavin" /><pair ddi="false" e1="DDI-PubMed.10064571.s2.e0" e2="DDI-PubMed.10064571.s2.e0" /><pair ddi="false" e1="DDI-PubMed.10064571.s2.e0" e2="DDI-PubMed.10064571.s2.e1" /><pair ddi="false" e1="DDI-PubMed.10064571.s2.e0" e2="DDI-PubMed.10064571.s2.e2" /><pair ddi="false" e1="DDI-PubMed.10064571.s2.e1" e2="DDI-PubMed.10064571.s2.e1" /><pair ddi="false" e1="DDI-PubMed.10064571.s2.e1" e2="DDI-PubMed.10064571.s2.e2" /></sentence><sentence text=" Additionally, tam is metabolically activated by hepatic CYP3A, forming a reactive intermediate that binds covalently to proteins" /><sentence text=" Tam and 4-hydroxyandrostenedione (4-OH-A) are currently used to treat breast cancer, and it has been contemplated that 4-OH-A be given concurrently with tam to contravene potential tumor resistance to tam"><entity charOffset="9-33" id="DDI-PubMed.10064571.s4.e0" text="4-hydroxyandrostenedione" /><entity charOffset="35-41" id="DDI-PubMed.10064571.s4.e1" text="4-OH-A" /><entity charOffset="120-126" id="DDI-PubMed.10064571.s4.e2" text="4-OH-A" /><pair ddi="false" e1="DDI-PubMed.10064571.s4.e0" e2="DDI-PubMed.10064571.s4.e0" /><pair ddi="false" e1="DDI-PubMed.10064571.s4.e0" e2="DDI-PubMed.10064571.s4.e1" /><pair ddi="false" e1="DDI-PubMed.10064571.s4.e0" e2="DDI-PubMed.10064571.s4.e2" /><pair ddi="false" e1="DDI-PubMed.10064571.s4.e1" e2="DDI-PubMed.10064571.s4.e1" /><pair ddi="false" e1="DDI-PubMed.10064571.s4.e1" e2="DDI-PubMed.10064571.s4.e2" /></sentence><sentence text=" Because alterations in tam metabolism may influence its therapeutic efficacy, the effect of 4-OH-A on tam metabolism was examined"><entity charOffset="93-99" id="DDI-PubMed.10064571.s5.e0" text="4-OH-A" /></sentence><sentence text=" Incubation of tam with liver microsomes from phenobarbital-treated rats, in the presence of 4-OH-A (10-100 microM), resulted in marked inhibition of tam-N-demethylation and tam covalent binding and in decreased tam-N-oxide accumulation; however, there was no inhibition of the formation of 4-hydroxy-tam and of 3,4-dihydroxytamoxifen"><entity charOffset="46-59" id="DDI-PubMed.10064571.s6.e0" text="phenobarbital" /><entity charOffset="93-99" id="DDI-PubMed.10064571.s6.e1" text="4-OH-A" /><entity charOffset="212-223" id="DDI-PubMed.10064571.s6.e2" text="tam-N-oxide" /><entity charOffset="312-334" id="DDI-PubMed.10064571.s6.e3" text="3,4-dihydroxytamoxifen" /><pair ddi="false" e1="DDI-PubMed.10064571.s6.e0" e2="DDI-PubMed.10064571.s6.e0" /><pair ddi="false" e1="DDI-PubMed.10064571.s6.e0" e2="DDI-PubMed.10064571.s6.e1" /><pair ddi="false" e1="DDI-PubMed.10064571.s6.e0" e2="DDI-PubMed.10064571.s6.e2" /><pair ddi="false" e1="DDI-PubMed.10064571.s6.e0" e2="DDI-PubMed.10064571.s6.e3" /><pair ddi="false" e1="DDI-PubMed.10064571.s6.e1" e2="DDI-PubMed.10064571.s6.e1" /><pair ddi="false" e1="DDI-PubMed.10064571.s6.e1" e2="DDI-PubMed.10064571.s6.e2" /><pair ddi="false" e1="DDI-PubMed.10064571.s6.e1" e2="DDI-PubMed.10064571.s6.e3" /><pair ddi="false" e1="DDI-PubMed.10064571.s6.e2" e2="DDI-PubMed.10064571.s6.e2" /><pair ddi="false" e1="DDI-PubMed.10064571.s6.e2" e2="DDI-PubMed.10064571.s6.e3" /></sentence><sentence text=" These findings indicate that 4-OH-A inhibits CYP3A, but not P-450(s) that catalyze tam 4-hydroxylation" /><sentence text=" The diminished tam-N-oxide accumulation could be due to decreased N-oxide formation and/or due to increased N-oxide reduction"><entity charOffset="16-27" id="DDI-PubMed.10064571.s8.e0" text="tam-N-oxide" /><entity charOffset="67-74" id="DDI-PubMed.10064571.s8.e1" text="N-oxide" /><entity charOffset="109-116" id="DDI-PubMed.10064571.s8.e2" text="N-oxide" /><pair ddi="false" e1="DDI-PubMed.10064571.s8.e0" e2="DDI-PubMed.10064571.s8.e0" /><pair ddi="false" e1="DDI-PubMed.10064571.s8.e0" e2="DDI-PubMed.10064571.s8.e1" /><pair ddi="false" e1="DDI-PubMed.10064571.s8.e0" e2="DDI-PubMed.10064571.s8.e2" /><pair ddi="false" e1="DDI-PubMed.10064571.s8.e1" e2="DDI-PubMed.10064571.s8.e1" /><pair ddi="false" e1="DDI-PubMed.10064571.s8.e1" e2="DDI-PubMed.10064571.s8.e2" /></sentence><sentence text=" Incubation of tam-N-oxide with liver microsomes containing heat-inactivated flavin-containing monooxygenase demonstrated that 4-OH-A increases the accumulation of tam, possibly by diminishing its P-450-mediated metabolism"><entity charOffset="15-26" id="DDI-PubMed.10064571.s9.e0" text="tam-N-oxide" /><entity charOffset="77-83" id="DDI-PubMed.10064571.s9.e1" text="flavin" /><pair ddi="false" e1="DDI-PubMed.10064571.s9.e0" e2="DDI-PubMed.10064571.s9.e0" /><pair ddi="false" e1="DDI-PubMed.10064571.s9.e0" e2="DDI-PubMed.10064571.s9.e1" /></sentence><sentence text=" Kinetic studies indicate that 4-OH-A is a competitive inhibitor of CYP3A, but not a time-dependent inactivator"><entity charOffset="31-37" id="DDI-PubMed.10064571.s10.e0" text="4-OH-A" /></sentence><sentence text=" Consequently, the concurrent treatment of tam and 4-OH-A may result in increased tam half-life and thus could potentiate the therapeutic efficacy of tam and diminish the potential side effects of tam by inhibiting its covalent binding to proteins and possibly to DNA"><entity charOffset="51-57" id="DDI-PubMed.10064571.s11.e0" text="4-OH-A" /></sentence><sentence text="" /></document>